| Inhibit              | Group         | Classification          | Subclass/Generation/Type                  | Antibiotics Examples (Listed Horizontally)                                                                 | Main Target Systems / Infections                                                                 | Key Notes                                                                 |
|----------------------|---------------|-------------------------|-------------------------------------------|------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| **Cell Wall Synthesis** | Beta Lactams | Penicillins            | Natural Penicillins                       | Penicillin G, Penicillin V                                                                                 | Gram-positive cocci (e.g., Streptococcus pyogenes, S. agalactiae), some anaerobes (e.g., Clostridium perfringens); infections like pharyngitis, skin/soft tissue, syphilis | Bactericidal; time-dependent killing; hypersensitivity reactions (e.g., rash, anaphylaxis); resistance via beta-lactamase hydrolysis; avoid in penicillin allergies |
|                      |               |                        | Antistaphylococcal Penicillins            | Procaine Penicillin G, Benzathine Penicillin G, Methicillin, Nafcillin, Oxacillin, Cloxacillin, Dicloxacillin, Flucloxacillin | Gram-positive (e.g., S. aureus including penicillinase-producing, but not MRSA); skin/soft tissue infections, osteomyelitis | Bactericidal; stable against penicillinase; interstitial nephritis; resistance via mecA gene (MRSA); hemolytic anemia |
|                      |               |                        | Aminopenicillins (Broad Spectrum)         | Ampicillin, Amoxicillin                                                                                    | Gram-positive (e.g., Enterococcus faecalis) and some Gram-negative (e.g., E. coli, H. influenzae, Listeria); respiratory, urinary tract, meningitis | Bactericidal; often combined with beta-lactamase inhibitors; hypersensitivity; GI upset; resistance via beta-lactamase |
|                      |               |                        |                                           | Co-Amoxiclav (Amoxicillin/Clavulanate), Ampicillin/Sulbactam                                              | Enhanced coverage against beta-lactamase producers (e.g., S. aureus, E. coli, Klebsiella); polymicrobial infections like intra-abdominal, bite wounds | Bactericidal; clavulanate/sulbactam inhibit beta-lactamases; diarrhea common; monitor for liver function |
|                      |               |                        | Anti-Pseudomonal Penicillins              |                                                                                                            |                                                                                                  |                                                                           |
|                      |               |                        | Carboxy-Penicillins                       | Ticarcillin, Carbenicillin                                                                                 | Gram-negative including Pseudomonas aeruginosa; complicated UTIs, sepsis                         | Bactericidal; thrombocytopenia risk; resistance via altered porins/efflux |
|                      |               |                        | Ureidopenicillins                         | Piperacillin, Mezlocillin, Azlocillin                                                                      | Broad-spectrum including Pseudomonas; hospital-acquired infections, pneumonia                    | Bactericidal; often with tazobactam; hypersensitivity; electrolyte imbalances |
|                      |               |                        | Combination                               | Piperacillin/Tazobactam, Ticarcillin/Clavulanate                                                           | Extended Gram-negative, anaerobes, Pseudomonas; empiric therapy for sepsis, intra-abdominal infections | Bactericidal; tazobactam/clavulanate protect against beta-lactamases; monitor renal function; resistance in ESBL producers |
|                      |               | Cephalosporins         | 1st Generation                            | Cefadroxil, Cephalexin, Cephradine, Cefazolin                                                              | Gram-positive (e.g., S. aureus, Streptococci), some Gram-negative (e.g., E. coli, Klebsiella); surgical prophylaxis, skin infections, UTIs | Bactericidal; low cross-allergenicity with penicillins (~1-3%); disulfiram-like reaction with alcohol in some; resistance via cephalosporinase |
|                      |               |                        | 2nd Generation                            | Cefaclor, Cefuroxime, Cefprozil, Cefoxitin                                                                 | Enhanced Gram-negative (e.g., H. influenzae, Enterobacter), anaerobes (cefoxitin); respiratory, intra-abdominal infections | Bactericidal; good for community-acquired pneumonia; GI side effects; resistance via extended-spectrum beta-lactamases (ESBL) |
|                      |               |                        | 3rd Generation                            | Ceftazidime, Cefotaxime, Cefoperazone, Ceftazidime/Avibactam, Cefixime, Cefdinir, Cefpodoxime, Cefpirome  | Broad Gram-negative (e.g., Pseudomonas for ceftazidime), some Gram-positive; meningitis, hospital-acquired pneumonia | Bactericidal; crosses blood-brain barrier (e.g., ceftriaxone); pseudolithiasis with ceftriaxone; resistance via carbapenemases |
|                      |               |                        | 4th Generation                            | Cefepime                                                                                                   | Broad including Pseudomonas, some ESBL producers; nosocomial infections, febrile neutropenia   | Bactericidal; neurotoxicity at high doses; better against AmpC beta-lactamases |
|                      |               |                        | 5th Generation                            | Ceftobiprole, Ceftaroline, Ceftolozane/Tazobactam                                                          | MRSA, Pseudomonas (ceftolozane); complicated skin infections, pneumonia                          | Bactericidal; tazobactam enhances vs. beta-lactamases; agranulocytosis risk; emerging resistance monitored |
|                      |               | Monobactams            |                                           | Aztreonam                                                                                                  | Gram-negative aerobes (e.g., Pseudomonas, Enterobacteriaceae); hospital-acquired infections, UTIs | Bactericidal; safe in penicillin allergies; no Gram-positive/anaerobe coverage; resistance via efflux/porin loss |
|                      |               | Carbapenems            |                                           | Imipenem/Cilastatin, Meropenem, Doripenem, Ertapenem                                                       | Broadest spectrum (Gram-positive/negative, anaerobes, except MRSA/Mycoplasma); life-threatening infections, sepsis | Bactericidal; cilastatin prevents renal metabolism; seizures with imipenem; resistance via carbapenemases (e.g., KPC, NDM) |
|                      | Non-Beta Lactams | Glycopeptide Antibiotics |                                         | Vancomycin, Teicoplanin, Telavancin, Dalbavancin, Oritavancin                                              | Gram-positive (e.g., MRSA, Enterococci); endocarditis, skin infections, C. difficile (oral vancomycin) | Bactericidal (exposure-dependent); red man syndrome; nephrotoxicity; resistance via D-Ala-D-Lac (VRE) |
|                      |               | Others                 |                                           | Fosfomycin, Bacitracin, Cycloserine, Zosurabalpin                                                          | Gram-negative (fosfomycin for UTIs), topical Gram-positive (bacitracin); MDR Acinetobacter (zosurabalpin) | Bactericidal; fosfomycin oral for uncomplicated UTIs; zosurabalpin in trials (2025 phase 3); resistance via altered transport |
| **Cell Membrane**    |               |                        |                                           | Colistin, Daptomycin                                                                                       | Gram-negative (colistin for MDR Pseudomonas/Acinetobacter), Gram-positive (daptomycin for MRSA skin/bloodstream) | Bactericidal; nephrotoxicity (colistin); myopathy (daptomycin); resistance via LPS modification (colistin) |
| **Protein Synthesis** | 30S          | Tetracyclines          |                                           | Tetracycline, Oxytetracycline, Doxycycline, Minocycline                                                    | Broad (Gram-positive/negative, atypicals like Rickettsia, Mycoplasma); acne, Lyme disease, respiratory infections | Bacteriostatic; photosensitivity; tooth discoloration in children; resistance via efflux; contraindicated in pregnancy |
|                      |               | Glycylcyclines         |                                           | Tigecycline                                                                                                | Broad including MDR; complicated skin/intra-abdominal infections                                 | Bacteriostatic; nausea; no Pseudomonas coverage; resistance via efflux   |
|                      |               | Aminoglycosides        |                                           | Streptomycin, Neomycin, Amikacin, Gentamicin, Tobramycin, Plazomicin                                      | Aerobic Gram-negative (e.g., Pseudomonas, Enterobacteriaceae); synergy in endocarditis          | Bactericidal (concentration-dependent); ototoxicity/nephrotoxicity; resistance via enzymatic modification; monitor levels |
|                      | 50S          | Macrolides             |                                           | Erythromycin, Clarithromycin, Azithromycin, Spiramycin, Josamycin                                          | Gram-positive, atypicals (e.g., Legionella, Mycoplasma); respiratory, STIs                       | Bacteriostatic; QT prolongation; GI upset; resistance via erm gene (MLS resistance); safe in pregnancy |
|                      |               | Ketolides              |                                           | Telithromycin                                                                                              | Similar to macrolides; community-acquired pneumonia                                              | Bacteriostatic; hepatotoxicity; visual disturbances; resistance similar to macrolides |
|                      |               | Chloramphenicol        |                                           | Chloramphenicol                                                                                            | Broad (e.g., H. influenzae, meningitis); typhoid, brain abscess                                  | Bacteriostatic; aplastic anemia; gray baby syndrome; contraindicated in neonates/pregnancy |
|                      |               | Oxazolidinones         |                                           | Linezolid, Tedizolid                                                                                       | Gram-positive (e.g., MRSA, VRE); skin infections, pneumonia                                      | Variable (bacteriostatic/cidal); thrombocytopenia; serotonin syndrome with SSRIs; resistance via target mutation |
|                      |               | Lincosamides           |                                           | Clindamycin                                                                                                | Gram-positive, anaerobes (e.g., Bacteroides); skin, bone, intra-abdominal infections             | Bacteriostatic; C. difficile risk; good bone penetration; inducible resistance (D-test) |
|                      |               | Streptogramins         |                                           | Quinupristin/Dalfopristin, Pristinamycin                                                                   | Gram-positive (e.g., VRE, MRSA); serious skin infections                                         | Bacteriostatic; arthralgia/myalgia; resistance via MLS mechanism         |
|                      |               | Others                 |                                           | Fusidic Acid, Mupirocin, Retapamulin                                                                       | Gram-positive (e.g., S. aureus); topical for skin infections                                     | Bacteriostatic; fusidic acid for osteomyelitis; local irritation; resistance via target alteration |
| **Topoisomerase**    |               | Quinolones             |                                           | Nalidixic Acid, Cinoxacin                                                                                  | Gram-negative; UTIs                                                                      | Bactericidal; limited use; resistance via target mutation                 |
|                      |               | Fluoroquinolones       | Second                                    | Ciprofloxacin, Norfloxacin, Ofloxacin                                                                      | Gram-negative (e.g., Pseudomonas, Enterobacteriaceae); UTIs, respiratory, GI infections          | Bactericidal (concentration-dependent); tendon rupture; QT prolongation; contraindicated in children/pregnancy; resistance via efflux/mutation |
|                      |               |                        | Third                                     | Levofloxacin                                                                                               | Broad including atypicals; pneumonia, sinusitis                                                  | Similar to second gen; phototoxicity; emerging resistance                |
|                      |               |                        | Fourth                                    | Moxifloxacin, Gemifloxacin, Gatifloxacin                                                                   | Enhanced Gram-positive/anaerobes; respiratory infections                                         | Bactericidal; ocular toxicity (gatifloxacin); resistance monitored       |
|                      |               |                        | Related (Novel Topoisomerase Inhibitors)  | Gepotidacin                                                                                                | Gram-negative (e.g., E. coli); uncomplicated UTIs in females ≥12                                 | Bactericidal; approved 2025; new class (triazaacenaphthylene); no cross-resistance; GI side effects; ongoing monitoring for resistance |
| **Nucleic Acid Synthesis** | Antifolates | Sulfonamides           |                                           | Sulfamethoxazole, Sulfadiazine, Silver Sulfadiazine, Sulfadoxine, Mafenide, Sulfacetamide                 | Broad (Gram-positive/negative, some protozoa); UTIs, burns, toxoplasmosis                        | Bacteriostatic; kernicterus in neonates; hypersensitivity (sulfa allergy); resistance via PABA overproduction |
|                      |               | DHFR Inhibitor         |                                           | Trimethoprim, Pyrimethamine                                                                                | Broad; UTIs, malaria (pyrimethamine)                                                     | Bacteriostatic; hyperkalemia; resistance via enzyme mutation             |
|                      |               | CO                     |                                           | Co-Trimoxazole, Sulfadoxine/Pyrimethamine                                                                  | Enhanced synergy; Pneumocystis pneumonia, UTIs                                           | Bacteriostatic; bone marrow suppression; contraindicated in pregnancy third trimester |
|                      | RNA Polymerase Inhibitors |                        |                                         | Rifampin, Rifaximin, Fidaxomicin                                                                           | Mycobacteria (rifampin for TB), C. difficile (fidaxomicin), travelers' diarrhea (rifaximin)      | Bactericidal (rifampin); orange body fluids; hepatotoxicity; resistance via RNA pol mutation; fidaxomicin low recurrence for C. diff
